KalVista Pharma Files Definitive Proxy Statement
Ticker: KALV · Form: DEF 14A · Filed: Aug 22, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | DEF 14A |
| Filed Date | Aug 22, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
Related Tickers: KALV
TL;DR
KalVista Proxy Statement filed. Vote on directors & auditors Oct 3rd.
AI Summary
KalVista Pharmaceuticals, Inc. filed its definitive proxy statement on August 22, 2024, for its annual meeting of stockholders on October 3, 2024. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, executive pay, and key decisions to be made at the upcoming annual meeting, impacting their investment.
Risk Assessment
Risk Level: low — This is a routine proxy filing providing information to shareholders and does not inherently introduce new business risks.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- October 3, 2024 (date) — Annual Meeting Date
- August 22, 2024 (date) — Filing Date
- Carbylan Therapeutics, Inc. (company) — Former Company Name
- Carbylan Biosurgery, Inc (company) — Former Company Name
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the definitive proxy statement for KalVista Pharmaceuticals, Inc.'s annual meeting of stockholders.
When is the annual meeting of stockholders scheduled to take place?
The annual meeting of stockholders is scheduled to take place on October 3, 2024.
Who is the filer of this proxy statement?
The filer of this proxy statement is KalVista Pharmaceuticals, Inc.
What are some of the key items to be voted on at the meeting?
Key items to be voted on include the election of directors and the ratification of the independent registered public accounting firm.
What was KalVista Pharmaceuticals, Inc. formerly known as?
KalVista Pharmaceuticals, Inc. was formerly known as Carbylan Therapeutics, Inc. and Carbylan Biosurgery, Inc.
Filing Stats: 4,943 words · 20 min read · ~16 pages · Grade level 11.5 · Accepted 2024-08-22 16:08:50
Key Financial Figures
- $0.001 — of KalVista are shares of common stock, $0.001 par value per share (the common stock )
Filing Documents
- d791142ddef14a.htm (DEF 14A) — 488KB
- g791142g42g42.jpg (GRAPHIC) — 135KB
- g791142g43g43.jpg (GRAPHIC) — 124KB
- g791142snap1.jpg (GRAPHIC) — 7KB
- 0001193125-24-205356.txt ( ) — 835KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 27
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 36 ADDITIONAL INFORMATION 39 Table of Contents KALVISTA PHARMACEUTICALS, INC. 55 Cambridge Parkway Suite 901E Cambridge, MA 02142 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS October 3, 2024 We have sent you this Proxy Statement and the enclosed Proxy Card because the Board of Directors (the Board ) of KalVista Pharmaceuticals, Inc. (referred to herein as the Company , KalVista , we , us or our ) is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders (the Annual Meeting ) to be held via a virtual meeting. You will be able to participate in the Annual Meeting and vote during the Annual Meeting via live webcast by visiting www.virtualshareholdermeeting.com/KALV2024 on October 3, 2024 at 9:30 a.m. Eastern Time, and any adjournments, rescheduling or postponement thereof. This Proxy Statement (the Proxy Statement ) summarizes information about the proposals to be considered at the Annual Meeting and other information you may find useful in determining how to vote. The Proxy Card (the Proxy Card ) is a means by which you may vote your shares or authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews. We may retain outside consultants to solicit proxies on our behalf as well. All costs of solicitation of proxies will be borne by us. Brokers, custodians and fiduciaries will be requested to forward proxy soliciting material to the owners of stock held in their names, and we will reimburse them for their reasonable out-of-pocket expenses incurred in connection with the distribution of proxy materials. The only outstanding voting securities of KalVista are shares of common stock, $0.001 par value per share (the common stock ), of which there